{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:30:40Z","timestamp":1786984240901,"version":"build-2736575974"},"reference-count":17,"publisher":"Codon Publications","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.aller.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T10:38:50Z","timestamp":1530873530000},"page":"303-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events"],"prefix":"10.15586","volume":"47","author":[{"given":"Jesus","family":"Miranda Poma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Ostios Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Villamayor Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"D\u2019errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","reference":[{"key":"10.1016\/j.aller.2018.04.005_bib0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (IRAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.aller.2018.04.005_bib0095","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0100","first-page":"1","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0110","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.aller.2018.04.005_bib0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.aller.2018.04.005_bib0125","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.aller.2018.04.005_bib0135","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.aller.2018.04.005_bib0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/COC.0000000000000059","article-title":"Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC)","volume":"38","author":"Langer","year":"2015","journal-title":"Am J Clin Oncol [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"ScienceDirect immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2017","journal-title":"Eur J Cancer [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0150","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.30501","article-title":"Safety and efficacy of nivolumab in the treatment of cancers: a meta-analysis of 27 prospective clinical trials","volume":"140","author":"Tie","year":"2017","journal-title":"Int J cancer [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther [Internet]"},{"key":"10.1016\/j.aller.2018.04.005_bib0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","article-title":"Ipilimumab in the treatment of metastatic melanoma: management of adverse events","volume":"7","author":"Della Vittoria Scarpati","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.aller.2018.04.005_bib0165","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.aller.2018.04.005_bib0170","volume":"33","author":"Horvat","year":"2015","journal-title":"Immune-related adverse events need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center"}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030105461830082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030105461830082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T17:52:01Z","timestamp":1609437121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030105461830082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S030105461830082X"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2018.04.005","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events","name":"articletitle","label":"Article Title"},{"value":"Allergologia et Immunopathologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aller.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEICAP. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}